Ae­tion to col­lab­o­rate with UK's NICE on RWE; 4D's cys­tic fi­bro­sis gene ther­a­py cleared for clin­i­cal tri­als

New York-based re­al world ev­i­dence, or RWE, firm Ae­tion is team­ing up with the Na­tion­al In­sti­tute for Health and Care Ex­cel­lence in the Unit­ed King­dom to an­a­lyze da­ta such as hos­pi­tal records, pre­scrip­tion records and more to study clin­i­cal ef­fec­tive­ness and fill gaps in ev­i­dence.

As Ae­tion CEO Car­olyn Mag­ill told End­points News, the com­pa­ny’s goal is to col­lect ev­i­dence that would be hard­er to get out­side of a con­trolled set­ting, such as a clin­i­cal tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER